Xconomy’s Digital Events →
December 3, 2020 · New York
Matthew Scholz is the CEO of Immusoft, a (currently) Seattle based biotech startup that is commercializing technology to program the human immune system.
If Seattle is to occupy a future place of dominance in the biotech world, it must foster more of an “incubator” culture. There is a “valley of death” between the well-funded... Read more »
Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.